During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
全部重症,使用后 68%改善,13死亡。
之前中国的新冠重症死亡率是 17-78%,WHO公布世界新冠重症死亡率50%左右。
这个效果比圈内小道消息传的要好。
原文:Jonathan Grein et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. NEJM 2020;
是,等中国的了,前段是听说效果没那么明显,至少没有提前使用,就证明不是极好的特效药。
曹老师的这份试验设计是很严谨的,全世界医学同仁都很期待数据公开的那天。
重症患者 肺都变玻璃了。一只脚已经踏进鬼门关了
因为是同情药,以及没有对照,他把并发症都算是副作用了,查了之前国内的报道,新冠肺炎的并发症也有这些症状
不是中国的那个实验。只是同情治疗的研究。中国的双盲在进行中。
这药可能有一定效果,但完全谈不上是特效药。
居然有人点灭你?
没事,毕竟是美国药
那帮二狗子忒坏
During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
少打%,你看之前我也用的百分之多少。帖子手机端不好改
准确来说叫不良反应 不是副作用
但也不是严格的循证医学实验